AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

Piper Sandler raised the firm’s price target on Teva (TEVA) to $30 from $23 and keeps an Overweight rating on the shares after meeting with ...